A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects
Latest Information Update: 15 Apr 2022
At a glance
- Drugs TS-172 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Taisho Pharmaceutical
- 11 Apr 2022 Status changed from recruiting to completed.
- 18 Aug 2021 Status changed from not yet recruiting to recruiting.
- 03 Aug 2021 New trial record